These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 28148261)

  • 1. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
    Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
    Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition.
    Chandrakesan P; Weygant N; May R; Qu D; Chinthalapally HR; Sureban SM; Ali N; Lightfoot SA; Umar S; Houchen CW
    Oncotarget; 2014 Oct; 5(19):9269-80. PubMed ID: 25211188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer.
    Sureban SM; May R; Qu D; Weygant N; Chandrakesan P; Ali N; Lightfoot SA; Pantazis P; Rao CV; Postier RG; Houchen CW
    PLoS One; 2013; 8(9):e73940. PubMed ID: 24040120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
    Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
    Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
    Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
    Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells through the Inhibition of DCLK1.
    Sakaguchi M; Hisamori S; Oshima N; Sato F; Shimono Y; Sakai Y
    Mol Cancer Res; 2016 Apr; 14(4):354-62. PubMed ID: 26747706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.
    Dandawate P; Ghosh C; Palaniyandi K; Paul S; Rawal S; Pradhan R; Sayed AAA; Choudhury S; Standing D; Subramaniam D; Padhye SB; Gunewardena S; Thomas SM; Neil MO; Tawfik O; Welch DR; Jensen RA; Maliski S; Weir S; Iwakuma T; Anant S; Dhar A
    Gastroenterology; 2019 Dec; 157(6):1646-1659.e11. PubMed ID: 31442435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dclk1 distinguishes between tumor and normal stem cells in the intestine.
    Nakanishi Y; Seno H; Fukuoka A; Ueo T; Yamaga Y; Maruno T; Nakanishi N; Kanda K; Komekado H; Kawada M; Isomura A; Kawada K; Sakai Y; Yanagita M; Kageyama R; Kawaguchi Y; Taketo MM; Yonehara S; Chiba T
    Nat Genet; 2013 Jan; 45(1):98-103. PubMed ID: 23202126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression.
    Liang Z; Ge Y; Li J; Bai Y; Xiao Z; Yan R; An G; Zhang D
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):342. PubMed ID: 38980538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-lived intestinal tuft cells serve as colon cancer-initiating cells.
    Westphalen CB; Asfaha S; Hayakawa Y; Takemoto Y; Lukin DJ; Nuber AH; Brandtner A; Setlik W; Remotti H; Muley A; Chen X; May R; Houchen CW; Fox JG; Gershon MD; Quante M; Wang TC
    J Clin Invest; 2014 Mar; 124(3):1283-95. PubMed ID: 24487592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting colon cancer stem cells using novel doublecortin like kinase 1 antibody functionalized folic acid conjugated hesperetin encapsulated chitosan nanoparticles.
    Lazer LM; Kesavan Y; Gor R; Ramachandran I; Pathak S; Narayan S; Anbalagan M; Ramalingam S
    Colloids Surf B Biointerfaces; 2022 Sep; 217():112612. PubMed ID: 35738074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA.
    Kantara C; O'Connell M; Sarkar S; Moya S; Ullrich R; Singh P
    Cancer Res; 2014 May; 74(9):2487-98. PubMed ID: 24626093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells.
    Zhang Y; Zoltan M; Riquelme E; Xu H; Sahin I; Castro-Pando S; Montiel MF; Chang K; Jiang Z; Ling J; Gupta S; Horne W; Pruski M; Wang H; Sun SC; Lozano G; Chiao P; Maitra A; Leach SD; Kolls JK; Vilar E; Wang TC; Bailey JM; McAllister F
    Gastroenterology; 2018 Jul; 155(1):210-223.e3. PubMed ID: 29604293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer.
    Ji D; Zhan T; Li M; Yao Y; Jia J; Yi H; Qiao M; Xia J; Zhang Z; Ding H; Song C; Han Y; Gu J
    Stem Cell Reports; 2018 Dec; 11(6):1506-1522. PubMed ID: 30449704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5/COX2 axis.
    Kim JH; Park SY; Jeon SE; Choi JH; Lee CJ; Jang TY; Yun HJ; Lee Y; Kim P; Cho SH; Lee JS; Nam JS
    Theranostics; 2022; 12(12):5258-5271. PubMed ID: 35910805
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
    Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
    Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dclk1+ small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal.
    Chandrakesan P; May R; Qu D; Weygant N; Taylor VE; Li JD; Ali N; Sureban SM; Qante M; Wang TC; Bronze MS; Houchen CW
    Oncotarget; 2015 Oct; 6(31):30876-86. PubMed ID: 26362399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells.
    Qu D; Johnson J; Chandrakesan P; Weygant N; May R; Aiello N; Rhim A; Zhao L; Zheng W; Lightfoot S; Pant S; Irvan J; Postier R; Hocker J; Hanas JS; Ali N; Sureban SM; An G; Schlosser MJ; Stanger B; Houchen CW
    PLoS One; 2015; 10(2):e0118933. PubMed ID: 25723399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
    Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
    Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.